Related references
Note: Only part of the references are listed.Expanding the p53 regulatory network: LncRNAs take up the challenge
Elena Grossi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2016)
Isatin derivatives with activity against apoptosis-resistant cancer cells
Nikolai M. Evdokimov et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study
Sandeep Rana et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges
Bin Yu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Small-molecule MDM2-p53 inhibitors: recent advances
Bian Zhang et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Discovery of Novel Isatin-Based p53 Inducers
P. Davidovich et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
KMT Set7/9 affects genotoxic stress response via the Mdm2 axis
Larissa Lezina et al.
ONCOTARGET (2015)
Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms
Mary Ann Allen et al.
ELIFE (2014)
Targeting p53 by small molecules in hematological malignancies
Manujendra N. Saha et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Qingjie Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
Yong S. Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
miR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress
L. Lezina et al.
CELL DEATH & DISEASE (2013)
Lysine-specific modifications of p53: a matter of life and death?
Diana Marouco et al.
ONCOTARGET (2013)
DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity
Tatiana N. Moiseeva et al.
ONCOTARGET (2013)
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Mark Wade et al.
NATURE REVIEWS CANCER (2013)
Structural insights into the dual-targeting mechanism of Nutlin-3
Jae-Sun Shin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Proteomic analysis of the 20S proteasome (PSMA3)-interacting proteins reveals a functional link between the proteasome and mRNA metabolism
Olga A. Fedorova et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells
Shinji Endo et al.
CANCER SCIENCE (2011)
Molecular Mimicry-Based Repositioning of Nutlin-3 to Anti-Apoptotic Bcl-2 Family Proteins
Ji-Hyang Ha et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
The microRNA and p53 families join forces against cancer
N. A. Barlev et al.
CELL DEATH AND DIFFERENTIATION (2010)
Identification and Characterization of the First Small Molecule Inhibitor of MDMX
Damon Reed et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Transcriptional Regulation by p53
Rachel Beckerman et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3
Martin Michaelis et al.
CANCER RESEARCH (2009)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Yoko Tabe et al.
CLINICAL CANCER RESEARCH (2009)
Targeting the MDM2-p53 interaction for cancer therapy
Sanjeev Shangary et al.
CLINICAL CANCER RESEARCH (2008)
Methylation-acetylation interplay activates p53 in response to DNA damage
Gleb S. Ivanov et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin
Baoli Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation
Roman Kulikov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy
E Rayburn et al.
CURRENT CANCER DRUG TARGETS (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy
P Chène
NATURE REVIEWS CANCER (2003)
Hypophosphorylation of Mdm2 augments p53 stability
C Blattner et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases
NA Barlev et al.
MOLECULAR CELL (2001)
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms
R Stad et al.
EMBO REPORTS (2001)
Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53
QZ Zhu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment
JM Espinosa et al.
MOLECULAR CELL (2001)
The contribution of the acidic domain of MDM2 to p53 and MDM2 stability
M Argentini et al.
ONCOGENE (2001)
Share Paper
